| Outcome Measures: |
Primary: Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion), 12 weeks | Secondary: Change in plasma nitric oxide, 12 weeks|Change in plasma isoprostane, 12 weeks|Change in plasma nitric oxide after reperfusion injury., 12 weeks|Change in plasma isoprostane after reperfusion injury., 12 weeks|Change in plasma Intercellular Adhesion Molecule 1(ICAM-1), 12 weeks|Change in plasma Vascular Cell Adhesion Molecule 1 (VCAM-1), 12 weeks|Change in plasma Endothelin-1 (ET-1), 12 weeks|Change in plasma Leptin, 12 weeks|Change in plasma Adiponectin, 12 weeks|Change in plasma C-reactive protein (CRP), 12 weeks|Change in plasma Tumor Necrosis Factor alpha (TNF-α), 12 weeks|Change in plasma interleukin-6, 12 weeks|Change in plasma interleukin-2, 12 weeks|Change in weight, 12 weeks|Change in body composition (% of fat mass and % free fat mass), 12 weeks | Other: Change in Glycated Hemoglobin, 12 weeks|Change in Systolic Blood Pressure, 12 weeks|Change in Mean Arterial Blood Pressure, 12 weeks|Change in Waist Circumference, 12 weeks
|
